Abstract:The treatment of acute promyelocytic leukemia (APL) with all trans retinoic acid (ATRA) has set a model for the differentiation induction-based new therapy. Although a substantial body of data related to ATRA-induced differentiation mechanisms has been obtained, the molecular events down stream of RA receptor complexes remain obscure. With the goal to get further insights into regulatory networks underlying ATRA-induced differentiation in APL, we applied 2DG, MS and cDNA microarray combined with bioinformatics analysis such as self-organizing map(SOM) to profile NB4 cells treated with ATRA over 3 time points (0h, 12h, 48h). Our results showed that cell cycle was arrested and proliferation was suppressed. For instance, ;the Origin recognition complex subunit 3 involved in initiating DNA replication that make the cell switch to S phase was downregulated significantly at protein (67.55 times) and mRNA levels; Breast cancer type 2 susceptibility protein (BRCA2) that can interact with BRAF335 as the checkpoint of G2 / M phase was upregulated while mRNA expression unchanged. Our results showed that the expression of many proteins associated with Ca2+ signal pathway such as IP3 receptor isoform 1 and phospholipase C-β changed upon induction with ATRA, implying that Ca2+ signal pathways may play an important role during ATRA-induced APL cell differentiation. Our results also indicated that the cell apoptosis was inhibited in the process of ATRA-induced differentiation. For example, BFL1, one of the BCL-2 family and the main apoptosis repressor in neutrophils, was upregulated at protein and mRNA levels. BCL2-like13 is one of the BCL-2 families and its overexpression initiated the cell apoptosis pathway by activating caspase-3. It was downregulated at protein level. Our results revealed that the phosphopentose pathway and ribonucleotide synthesis were repressed obviously. The protein expressions of the key enzyme of phosphopentose pathway - Glucose-6-phosphate dehydrogenase and rate-limiting enzyme of purine nucleotide de novo synthesis - AICAR methylferase and adenylosuccinate synthetase were all downregulated remarkably. Moreover, the protein expression of nitricoxide synthase 2A was upregulated 236 times after 12 hours of treatment with ATRA. The dramatic changes imply that the effect of NO on the differentiation induced by ATRA deserves more investigation. In brief, the data presented above indicated the expression of a large number of genes and proteins is modulated upon effect of ATRA during ATRA-induced APL cell differentiation, resulting in a complex and well-organized network to ensured cell reprogramming.

Combination of Ethacrynic Acid and ATRA Triggers Differentiation and/or Apoptosis of Acute Myeloid Leukemia Cells through ROS

[Study on Matrine Alleviating Retinoic Acid Resistance in Acute Promyelocytic Leukemia].

Combination of Decitabine and ATRA in Newly Diagnosed Myelodysplastic Syndromes Subtype EB-Interim Analysis of a Multicenter, Randomized, Open-Label Trial

Combination of Enzastaurin and ATRA Exerts Dose-Dependent Dual Effects on ATRA-resistant Acute Promyelocytic Leukemia Cells.

Combined Application of Salinomycin and ATRA Induces Apoptosis and Differentiation of Acute Myeloid Leukemia Cells by Inhibiting WNT/β-Catenin Pathway

The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.

The HER2 Inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by Activating MEK/ERK Mediated RARα/STAT1 Axis

Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines

A Genomic and Proteomic Research for the Regulatory Networks of Atra-Induced Differentiation of Acute Promyelocytic Leukemia Cells

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

Enzastaurin Enhances ATRA-induced Differentiation of Acute Myeloid Leukemia Cells.

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.

Dihydromyricetin sensitizes human acute myeloid leukemia cells to retinoic acid-induced myeloid differentiation by activating STAT1

Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells

All-trans Retinoic Acid/as 2 O 3 Combination Yields a High Quality Remission and Survival in Newly Diagnosed Acute Promyelocytic Leukemia

[Everolimus Combined with All-Trans Retinoid Acid Reverses Drug Resistance in Acute Promyelocytic Leukemia NB4-R1 Cells].

Data from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-<i>Trans</i>-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis

Mechanisms Ofall-Trans Retinoic Acid-Induced Differentiation of Acute Promyelocytic Leukemia Cells

All-trans Retinoic Acid Enhances the Effect of 5-Aza-2′-deoxycytidine on P16ink4a Demethylation, and the Two Drugs Synergistically Activate Retinoic Acid Receptor Β Gene Expression in the Human Erythroleukemia K562 Cell Line

Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation